Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: a retrospective cohort study

Table 2 Description about leukemia subtypes and treatment strategies

Characteristics	whole period	phase A	phase B	phase C	phase D	p value
AML subtype
de novo AML	49	13	6	17	13	0.646
AML-MRC	33	13	5	8	7
t-MN	11	3	1	6	1
APL	5	1	2	1	1
CML-BC	1	1	0	0	0
ALL subtype
B-ALL	10	4	0	6	0	0.092
T-ALL	8	0	2	3	3
CML-BC	3	0	1	1	1
induction treatment for AML
SDAC with anthracycline^a	86	21	11	31	20	0.002
HDAC based treatments^a	11	9	1	0	1
anthracycline with ATRA	5	1	2	1	1
induction treatment for ALL
HyperCVAD-MA	17	5	4	8	0	0.002
other treatments	5	0	0	3	5

AML denotes acute myelogenous leukemia; AML-MRC AML with myeloid dysplasia related changes, t-MN treatment related myeloid neoplasia; APL acute promyelocytic leukemia, CML-BC chronic myeloid leukemia blast crisis, ALL acute lymphoblastic leukemia, Ph-ALL Philadelphia chromosome positive ALL, B-ALL B cell ALL, T-ALL T cell ALL, SDAC standard-dose cytarabine, HDAC high-dose cytarabine, ATRA all-trans retinoic acid, HyperCVAD-MA hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate, and cytarabine ^aSDAC means 100-200mg/ m2 of cytarabine and HDAC means more than 1-2g/ m2 of cytarabine

ISSN: 1471-2334